COMPASS THERAPEUTICS, INC.

Analyst Reco. Compass Therapeutics, Inc.

Equities

CMPX

US20454B1044

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
1.54 ^USD	-4.64%		-2.53%	-1.28%

13/05	Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	Top Premarket Gainers	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Starts Compass Therapeutics at Buy With $8 Price Target	31/23/31	MT
Stifel Initiates Compass Therapeutics at Buy With $9 Price Target	27/23/27	MT
EF Hutton Initiates Compass Therapeutics at Buy With $10.30 Price Target	16/22/16	MT
Raymond James Adjusts Price Target on Compass Therapeutics to $8 From $5, Maintains Outperform Rating	10/22/10	MT
HC Wainwright Adjusts Compass Therapeutics' Price Target to $10 From $12, Keeps Buy Rating	03/22/03	MT
HC Wainwright Assumes Compass Therapeutics at Buy, Price Target Set at $12	23/22/23	MT
SVB Leerink Adjusts Compass Therapeutics' Price Target to $11 from $9, Keeps Outperform Rating	05/22/05	MT
Ladenburg Thalmann Initiates Compass Therapeutics at Buy With $7 Price Target	15/22/15	MT
B. Riley Starts Compass Therapeutics at Buy with $10 PT, Says Well-Positioned to Benefit from Potential Biotech Sector Turnaround	19/22/19	MT
Raymond James Starts Compass Therapeutics at Outperform With $5 Price Target	22/21/22	MT
SVB Leerink Starts Compass Therapeutics at Outperform With $12 Price Target	20/21/20	MT
Wedbush Starts Compass Therapeutics at Outperform With $8 Price Target	15/21/15	MT
Roth Capital Initiates Compass Therapeutics at Buy Rating With $15 Price Target	20/21/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW